A Pennsylvania man has taken the manufacturers of Levaquin and Avelox to court, after he developed permanent peripheral neuropathy allegedly related to his use of the two fluoroquinolone antibiotics. The complaint claims that the Defendants’ failed to provide patients with proper notification regarding the drugs’ potentially serious side effects.

According to the filing, the Plaintiff was prescribed Avelox in July 2008 and Levaquin at various intervals from May 2008 through August 2008. He alleges that his use of the drugs caused or directly contributed  to the development of permanent peripheral neuropathy and related injuries.

The Plaintiff asserts that the warnings included on the labels for Levaquin and Avelox in 2008 were misleading, as they characterized peripheral neuropathy as a rare occurrence, and implied that the injury could be avoided by discontinuing the drug. In reality, the onset of peripheral neuropathy is often rapid, and not always reversible. The complaint also notes that the language regarding peripheral neuropathy was “buried at the end of a long list of adverse reactions” and not highlighted in a way that would benefit doctors or patients.

The lawsuit was originally filed in the U.S. District Court, Eastern District of Pennsylvania, on May 24th. However, court records indicate that the case has since been transferred to the U.S. District Court, District of Minnesota, where all federal peripheral neuropathy lawsuits involving Levaquin, Cipro and Avelox have been centralized for coordinated pretrial proceedings.

Fluoroquinolone Side Effects

Fluoroquinolone antibiotics, including Levaquin and Avelox, are indicated to treat pneumonia and other serious bacterial infections. Five years after this Plaintiff’s diagnosis, the U.S. Food & Drug Administration (FDA) required fluoroquinolone manufacturers to strengthen peripheral neuropathy warnings included on the label. According to the agency, the previous wording did not adequately describe the rapid onset of symptoms, or the fact that peripheral neuropathy associated with the antibiotics could be permanent.

Just last month, the agency advised that fluoroquinolones should not be used to treat sinusitis, bronchitis and uncomplicated urinary tract infections, after a review found that systemic use of the drugs can cause potentially debilitating and permanent side effects. According to the FDA, serious fluoroquinolone side effects can involve the tendons, muscles, joints, nerves, and central nervous system. These complications can occur together, and they may prove permanent in some patient. The labels are being updated with a new boxed warning to reflect these risks.

Legal Help for Those Harmed By Fluoroquinolone Antibiotics

Bernstein Liebhard LLP represents individuals who suffered peripheral neuropathy and other complications allegedly related to the use of Levaquin, Cipro or Avelox. To learn more, please call 877-779-1414.

Published June 28, 2016 by